Activation of cutaneous immunity by percutaneous absorption of chemical through the stratum corneum is well established; however, given the long dissolution half-life for beryllium metal and its alloys, we hypothesized that beryllium particles would have to colocalize with the cutaneous antigen-presenting cell
in the epidermis in order to activate a cell-mediated immune response.
Chai, "The roles of antigen-specificity, responsiveness to transforming growth factor-[beta] and antigen-presenting cell
subsets in tumour-induced expansion of regulatory T cells," Immunology, vol.
In this study, we demonstrated that photochemical treatment of Drosophila antigen-presenting cells
with UVADEX and UVA ex vivo can eliminate the infectivity of infectious agents and maintain or increase APC function.
It is unclear if the defect is primarily a T-cell aberration or if it is due to an antigen-presenting cell
CHS is a delayed-type immune response (Asherson & Ptak 1968) and has served as a useful model for investigating the allergen-specific immune responses of T cells and skin-associated antigen-presenting cells
(APC) (Nuriya et al.
Specifically, IL-12-induced secretion of IFNy from NK cells and T lymphocytes boosts the function of antigen-presenting cells
by increasing the class I and II MHC molecule expressions.
B lymphocytes as antigen-presenting cells
for CD4+ Tcell priming in vivo.
in the female reproductive tract: influence of the estrous cycle on antigen presentation by uterine epithelial and stromal cells.
A small peptide of the MBP nestles into a groove in the HLA-D molecule on an antigen-presenting cell
and the TCR, on an approaching immune T-cell, locks on to both.
Chong et al., "The chemokine receptor CCR7 mediates corneal antigen-presenting cell
trafficking," Molecular Vision, vol.
pDCs are efficient antigen-presenting cells
specialized in the production and secretion of type I interferons (IFNs) following their recognition of viruses or self-nucleic acids through Toll-like receptor (TLR) 7 and TLR9 [23, 32].
Under the deal, Janssen will secure rights to develop and commercialise ADC-1013, an agonistic fully human monoclonal antibody, that targets CD40, an immuno-stimulatory receptor found on antigen-presenting cells
such as dendritic cells.